|Datasheet||Specific References||Reviews||Related Products||Protocols|
|CHO cell-derived rhvWF (Catalog#10973-H08C)|
|0.2 μm filtered solution in PBS with 5% trehalose|
|This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human von Willebrand factor (rhvWF; Catalog#10973-H08C; aa 1-2813; NP_000543.2). The IgG fraction of the cell culture supernatant was purified by Protein A affinity chromatography.|
ELISA: 0.25-0.5 μg/mL
This antibody can be used at 0.25-0.5 μg/mL with the appropriate secondary reagents to detect vWF. The detection limit for vWF is approximately 10 ng/well.
IHC-P: 1-5 μg/mL
|This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free.|
Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.
Von Willebrand Factor (VWF) is a multimeric glycoprotein involved in hemostasis in blood, binds receptors on the surface of platelets and in connective tissue, thereby mediating the adhesion of platelets to sites of vascular injury. From studies it appears that VWF protein uncoils under these circumstances, decelerating passing platelets. VWF protein is deficient or defective in von Willebrand disease (VWD) and is involved in a large number of other diseases, including thrombosis, thrombotic thrombocytopenic purpura, Stroke, Heyde's syndrome, possibly hemolytic-uremic syndrome and so on.